Signacor Therapeutics

SignaCor Therapeutics, founded in 2024 by Chris Watson (CSO) and headquartered in Belfast, UK, is dedicated to developing advanced therapeutic solutions for hypertrophic cardiomyopathy (HCM). SignaCor's primary product offering is Cardiaza, an innovative injectable therapy designed to treat symptomatic hypertrophic cardiomyopathy (HCM). This first-in-class therapeutic leverages DNA methylation to target multiple underlying mechanisms contributing to the disease, such as pathological fibrosis and cardiomyocyte hypertrophy. Cardiaza is specifically intended for patients suffering from symptomatic HCM, a prevalent genetic condition affecting approximately 1 in 500 adults worldwide. SignaCor primarily serves markets in the United Kingdom and Europe, with plans to expand into North America and other international markets as development progresses. SignaCor operates within a business model that focuses on the development and commercialization of its flagship product, Cardiaza, targeting healthcare providers and institutions that treat cardiac patients. Revenue generation is anticipated through partnerships with medical facilities and potentially direct sales to hospitals and clinics specializing in cardiac care. Given the nature of the product, transactions are expected to occur via direct-to-consumer models and B2B agreements with healthcare institutions. The company is positioned to establish pricing plans based on the therapeutic benefits offered by Cardiaza, which addresses the underlying disease pathology of HCM. As a clinical-stage biotech firm, the monetization strategy will likely evolve following successful clinical trials and regulatory approvals, paving the way for market entry and revenue realization.

1. Seed

   Mar 10, 2026

   Amount

   $0.3M

   Investors

   Locked